Actionable insights into solid tumor cancers

 

Sema4 Solid Tumor Panel analyzes 161 of the most relevant cancer driver genes to help doctors find the right treatment, the first time. The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to test for actionable somatic mutations in solid tumors.

 

Highly accurate

99% sensitivity and specificity*

 

Comprehensive

>99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials†

Actionable

Delivers insights to guide targeted therapy or clinical trial selection

 

Advanced

Powered by the Oncomine platform, a next-generation sequencing solution used by leading global research institutions and clinical trials, including the NCI-MATCH trial

 

 

*Compared against a series of cases with known or previously-tested mutations by other NGS methods.

 Based on an analysis of actionable alterations from OncoKB. For additional information, please see Chakrevarty D, Gao K, Phillips S, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology. 2017.

 

 

Powerful insights to help personalize treatment

 

This test is designed to help identify appropriate targeted therapies and clinical trials. The Solid Tumor Panel tests for clinically significant mutations in solid tumor cancers, including

20+ genes found in

15+ guidelines

for solid tumor genetic testing

115+ genes included in

800+ clinical trials

worldwide

15+ genes associated with

30+ targeted therapies

that are approved by the FDA

 

View our provider brochure to learn more >>

 

Analyzes 161 of the most relevant cancer driver genes

 

Genes interrogated by the Solid Tumor Panel

Hotspot regions sequenced

87 genes

AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1

 


 

All coding exons sequenced

48 genes

ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

 


 

Copy number variations queried

43 genes

AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT

 


 

Copy number variations queried

43 genes

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

 

Testing includes microsatellite instability (MSI) analysis to identify patients who may be candidates for immunotherapy or MSI-indicated clinical trials

  • Designed for use in solid tumors
  • May help identify Lynch Syndrome in colon and endometrial cancers

Markers interrogated by the MSI analysis

Multiplexed markers   BAT‑25, BAT‑26, MONO‑27, NR‑21, NR‑24

 

Results are presented in a comprehensive report

 

Depending on the case and findings, the report provides insight into

  • Appropriate targeted therapies
  • Relevant clinical trials
  • MSI status
  • Resistance markers
  • Clinically relevant negative results
  • Patient prognosis

 

We are dedicated to helping every patient

access advanced genetic testing

 

Sema4 is contracted with all major national payors. For patients who are uninsured or underinsured, affordable payment plans, self-pay pricing, and other financial assistance options are also available.

 


 

Resources

 

Connect with us today

Kindly fill out the form below and we’ll schedule a time to discuss your needs. Or feel free to call us at 833-486-6260.
 



Oncomine is a trademark of Thermo Fisher Scientific Inc. All rights reserved. No clinical claims, sponsorship, endorsement, or affiliation by Thermo Fisher Scientific is implied herein. The data generated by Sema4 is the sole responsibility of Sema4. The Oncomine Comprehensive Tumor Profiling Assay was developed by leading cancer institutes and regulatory agencies, and distributed by Thermo Fisher to support the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial. To learn more, please see Lih CJ, Harrington RD, Sims DJ, et al. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn. 2017; 19: 313-327.